Enliven Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $316 | $0 |
Gross Profit | -81 | -74 | 158 | -80 |
EBITDA | -28,584 | -31,693 | -26,816 | -26,988 |
EBIT | -28,665 | -31,767 | -26,896 | -27,068 |
Net Income | -25,335 | -28,544 | -23,180 | -23,156 |
Net Change In Cash | 0 | 0 | 316 | 0 |
Free Cash Flow | -17,196 | -24,147 | -17,203 | -12,215 |
Cash | 119,437 | 101,705 | 124,117 | 100,621 |
Basic Shares | 52,105 | 50,051 | 49,858 | 48,267 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -317 | -297 | -622 | -99 |
EBITDA | -88,475 | -81,932 | -38,576 | -24,647 |
EBIT | -88,792 | -82,229 | -38,791 | -24,762 |
Net Income | -89,024 | -71,584 | -37,662 | -24,718 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -73,236 | -61,418 | -32,689 | -19,325 |
Cash | 124,117 | 100,141 | 75,536 | 110,024 |
Basic Shares | 47,073 | 35,546 | 6,249 | 7,815 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.49 |
2025-03-31 | -$0.57 |
2024-12-31 | -$0.46 |
